1FG0 Stock Chart & Stats
€6.60
-€0.15(-2.50%)
At close: 4:00 PM EDT
€6.60
-€0.15(-2.50%)
Day’s Range― - ―
52-Week Range€5.35 - €10.10
Previous CloseN/A
Volume0.00
Average Volume (3M)2.00
Market Cap
€24.27M
Enterprise Value-€38.76
Total Cash (Recent Filing)€91.32M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)0.1
Beta1.03
Next Earnings
Nov 09, 2026EPS Estimate
-3.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)58.19
Shares Outstanding4,049,124
10 Day Avg. Volume0
30 Day Avg. Volume2
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-1.18
Price to Sales (P/S)5.51
P/FCF Ratio-7.38
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€35.02Price Target Upside430.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-8.52
Revenue Forecast (FY)€5.97M
Bulls Say, Bears Say
Bulls Say
Differentiated Oncology PipelineEarly clinical activity and a companion imaging strategy give Kyntra a differentiated position in prostate cancer. If confirmed in the larger Phase II study, the combination could improve patient selection, support stronger development decisions, and create a more defensible therapeutic niche.
Clinical Development MilestonesBoth lead programs have defined development plans and identifiable milestones over the next several months. This advances the company beyond early discovery, creates multiple opportunities for clinical validation, and provides a clearer path toward selecting registrational strategies.
Reduced Financing ObligationsReducing the maximum financing payments and eliminating true-ups improves the predictability of future obligations. The capped remaining payments and release of some collateral should preserve more future royalty economics, strengthening liquidity management as clinical spending continues.
Bears Say
Sustained Revenue ContractionMeaningful revenue contraction indicates that current commercial or royalty income is not providing a dependable operating base. Continued dependence on development programs, rather than recurring revenue, increases execution pressure and makes future funding needs more sensitive to clinical timing.
Persistent Cash Burn And Weak Earnings QualityNegative operating and free cash flow means Kyntra continues consuming resources to advance its pipeline. Because reported profits are not converting into cash, earnings provide limited support for self-funded growth, leaving financial outcomes dependent on liquidity and capital allocation.
Negative Shareholders’ EquityPersistently negative equity reflects an accumulated deficit and leaves the company with a weak capital cushion. Although eliminating debt reduces leverage, the negative equity position can still constrain financial flexibility and raise the importance of maintaining adequate funding.
Kyntra Bio News
1FG0 FAQ
What was Kyntra Bio’s price range in the past 12 months?
Kyntra Bio lowest stock price was €5.35 and its highest was €10.10 in the past 12 months.
What is Kyntra Bio’s market cap?
Kyntra Bio’s market cap is €24.27M.
When is Kyntra Bio’s upcoming earnings report date?
Kyntra Bio’s upcoming earnings report date is Nov 09, 2026 which is in 38 days.
How were Kyntra Bio’s earnings last quarter?
Kyntra Bio released its earnings results on Aug 13, 2026. The company reported €2.613 earnings per share for the quarter, beating the consensus estimate of -€2.811 by €5.424.
Is Kyntra Bio overvalued?
According to Wall Street analysts Kyntra Bio’s price is currently Undervalued.
Does Kyntra Bio pay dividends?
Kyntra Bio does not currently pay dividends.
What is Kyntra Bio’s EPS estimate?
Kyntra Bio’s EPS estimate is -3.29.
How many shares outstanding does Kyntra Bio have?
Kyntra Bio has 4,049,124 shares outstanding.
What happened to Kyntra Bio’s price movement after its last earnings report?
Kyntra Bio reported an EPS of €2.613 in its last earnings report, beating expectations of -€2.811. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Kyntra Bio?
Currently, no hedge funds are holding shares in DE:1FG0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kyntra Bio
Kyntra Bio, Inc. functions as a biopharmaceutical enterprise, encompassing the entire process from the initial discovery and rigorous development of innovative treatments to their ultimate market introduction. The company's scientific focus delves into the complex biology of hypoxia-inducible factors (HIF) and connective tissue growth factors (CTGF). Through this research, Kyntra Bio strives to create groundbreaking therapies aimed at tackling conditions like anemia, various fibrotic disorders, and different forms of cancer. Established by Thomas B. Neff on September 29, 1993, the firm's main offices are situated in San Francisco, California.
1FG0 Company Deck
1FG0 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple meaningful clinical and operational positives: concrete Phase I/IST efficacy signals for FG-3246 (with a clear plan for a Phase II interim readout in Q4 2026), a finalized Phase III protocol and compelling subgroup data for roxadustat, a unique non-PSMA therapeutic + companion diagnostic position, and a positive swing to net income with a cash runway into 2028. Offsetting these were notable near-term financial headwinds (negative reported revenue and higher operating expenses), safety and biomarker confirmation risks that require larger data sets, enrollment and market dynamics uncertainty (Pluvicto adoption) and the dependence on partnering/capital for a registrational path for roxadustat. On balance, the highlights modestly outweigh the lowlights due to actionable clinical progress and a forthcoming near-term catalyst (FG-3246 interim) alongside sufficient cash runway to advance programs.View all DE:1FG0 earnings summaries1FG0 Stock 12 Month Forecast
Average Price Target
€35.02
▲(430.56% Upside)
Technical Analysis
Grace Therapeutics
―
―
OnKure Therapeutics
―
Senti Biosciences
―
Xilio Therapeutics
―